

**AMENDMENTS TO THE CLAIMS**

1-11. (Cancelled).

12. (Currently Amended) A method for ~~preventing~~, ameliorating or treating [[a]] an inflammatory bowel disease, comprising  
administering a composition comprising galactomannan and/or arabinogalactan to  
a patient suffering from said bowel disease.

13. (Canceled)

14. (Previously Presented) The method according to claim 12, wherein said  
galactomannan and/or arabinogalactan is administered with a protein.

15. (Previously Presented) The method according to claim 14, wherein the protein is  
one or more proteins selected from the group consisting of a soy protein, a milk protein, a yolk  
protein, an albumen protein, a wheat protein and a degraded product thereof.

16. (Currently Amended) A method for ~~preventing~~, ameliorating or treating irritable  
bowel syndrome, comprising  
administering a composition comprising galactomannan to a patient suffering  
from said irritable bowel syndrome.

17. (Previously Presented) The method according to claim 14, wherein said composition is administered as a liquid food.

18. (Previously Presented) The method according to claim 12, wherein the composition comprises degraded galactomannan as the galactomannan.

19. (Previously Presented) The method according to claim 14, wherein said galactomannan is degraded galactomannan.

20. (Previously Presented) The method according to claim 16, wherein the composition comprises degraded galactomannan as the galactomannan.

21. (Currently Amended) The method according to ~~claim 13~~ claim 12, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis, Crohn's disease and intestinal Behçet disease.

22. (Previously Presented) The method according to claim 14, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis, Crohn's disease and intestinal Behçet disease.

23-25. (Canceled)

26. (Previously Presented) The method according to claim 12, wherein said composition comprises galactomannan and does not comprise arabinogalactan.

27. (Previously Presented) The method according to claim 12, wherein said composition comprises arabinogalactan and does not comprise galactomannan.

28. (Previously Presented) The method according to claim 12, wherein said composition comprises galactomannan and arabinogalactan.

29. (New) The method according to claim 16, wherein said irritable bowel syndrome includes a diarrhea type, persistent constipation type and alternation type.